HbA1c Antikörper (Chain beta, N-Term)
Kurzübersicht für HbA1c Antikörper (Chain beta, N-Term) (ABIN7855705)
Target
Alle HbA1c Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- Chain beta, N-Term
-
Verwendungszweck
- Anti-h HbA1c 2403 SPTN-5
-
Spezifität
- Antibody recognizes human glycated hemoglobin A1
-
Kreuzreaktivität (Details)
- Does not recognize non-glycated hemoglobin A1.
-
Produktmerkmale
- Monoclonal mouse antibody, cultured in vitro under conditions free from animal-derived components.
-
Reinheit
- ≥ 95 %
-
Isotyp
- IgG1
-
-
-
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 5.0 mg/ml
-
Buffer
- 50 mM Na-citrate, pH 6.0, 0.9 % NaCI, 0.095 % NaN3 as a preservative
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Liquid, may turn slightly opaque during storage
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- 18 months from manufacturing at 2–8 °C
-
Haltbarkeit
- 18 months
-
-
- HbA1c (Glycated Hemoglobin HbA1c (HbA1c))
-
Andere Bezeichnung
- Glycated Hemoglobin HbA1c
-
Hintergrund
- Glycated hemoglobin (HbA1c) is formed in a non-enzymatic process during exposure to plasma glucose. Normal levels of glucose produce a normal amount of glycated hemoglobin. As the average amount of plasma glucose increases, the fraction of glycated hemoglobin increases in a predictable way. This serves as a marker for average blood glucose levels over the previous months prior to the measurement. The 2010 American Diabetes Association Standards of Medical Care in Diabetes added the HbA1c ≥ 48 mmol/mol (≥ 6.5 %) as another criterion for the diagnosis of diabetes.
Target
-